Rituximab for steroid-dependent nephrotic syndrome

• Tipo: Artigo em Revista Científica Internacional
• Data: 2010

Autores

Beco, A (Autor) Outra; Castro Ferreira, I (Autor) Outra; Luís Coentrão (Autor) FMUP; Ricardo Neto (Autor) FMUP; Sampaio, S (Autor) Outra; Pestana M (Autor) FMUP

Revista

Título: Clinical Nephrology

Vol. 74

Páginas: 308-310

ISSN: 0301-0430

Editora: Dustri-Verlag Dr. Karl Feistle

Indexação

ISI Web of Knowledge - 11 Citações

Scopus - 12 Citações

Outras Informações

ID Authenticus: P-003-26E

Abstract (EN): Minimal change disease (MCD) is characterized by marked sensitivity to glucocorticoid therapy. However, in 40 - 50% of all cases the disease presents with frequent relapses and needs repeated courses of steroids as well as additional immunosuppressive therapy including azathioprine, cyclophosphamide or cyclosporine. Because such regimens are associated with significant toxicity, the therapeutic challenge of this disease is to identify the treatment with the highest probability of producing a sustained remission with the lowest risk of toxicity. There is increasing evidence that rituximab may play an important role in the treatment of idiopathic nephrotic syndrome. Here, we present an adult patient with steroid-sensitive but high-dose steroid-dependent MCD beginning in childhood with a heavy history of multiple immunosuppressive therapy that was brought into 1 year sustained remission of proteinuria with two infusions of rituximab (375 mg/m(2)).

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 3